Session 11: Novel Therapies for CLL II: Harnessing the Power of the Immune System to Combat CLL

Monday, September 15, 2025

10:00 - 11:30 CEST

Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1

Co-Chair(s)

Arnon Kater, MD, PhD

Vice Chair, Hematologist & Principal Scientist
Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
Amsterdam, Noord-Holland, Netherlands
MB

Maria Teresa Bertilaccio, PhD

Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

10:00 - 10:15 CEST

Bispecific Antibodies
Speaker: Parag D. Jasani, MBBS, FRCP, FRCPath – Royal Free London NHS Trust and University College London NHS Trust
10:15 - 10:30 CEST

Metabolic Fitness of T-cells and CAR T-cells
Speaker: Helga Simon-Molas, PhD – Amsterdam University Medical Centers
10:30 - 10:45 CEST

CD19 Targeted CAR-T: Autologous & Allogeneic
Speaker: J. Joseph Melenhorst, PhD – Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland Clinic
10:45 - 11:00 CEST

CAR Therapies: Beyond T-cells and CD19 as the Target
Speaker: Sunil Acharya, PhD – The University of Texas MD Anderson Cancer Center
11:00 - 11:15 CEST

Panel Discussion With Interactivity and Audience Q&A
11:15 - 11:25 CEST

A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in chronic lymphocytic leukemia
Primary Author / Presenter: Andrew Lu, SB – Dana Farber Cancer Institute
11:25 - 11:30 CEST

Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study
Primary Author / Presenter: Marta Coscia, MD, PhD – Department of Medicine and Surgery, University of Insubria and Department of Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi